<SEC-DOCUMENT>0001193125-18-005986.txt : 20180108
<SEC-HEADER>0001193125-18-005986.hdr.sgml : 20180108
<ACCEPTANCE-DATETIME>20180108163204
ACCESSION NUMBER:		0001193125-18-005986
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20180108
DATE AS OF CHANGE:		20180108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CERUS CORP
		CENTRAL INDEX KEY:			0001020214
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				680262011
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-219727
		FILM NUMBER:		18516795

	BUSINESS ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520
		BUSINESS PHONE:		9252886000

	MAIL ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		STREET 2:		STE 300
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CERUS TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19960731
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d516993d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR> Registration No. 333-219727<BR> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$70,000,000 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516993g41z17.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into amendment No.&nbsp;3 to our sales agreement, or the sales agreement, with Cantor Fitzgerald&nbsp;&amp; Co., or Cantor,
relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, as amended to date, which we refer to as the amended sales agreement, we may offer and sell shares of our common stock under this
prospectus having an aggregate offering price of up to $70,000,000 from time to time through Cantor, acting as agent. As of immediately prior to the effectiveness of amendment No.&nbsp;3, shares of our common stock having an aggregate offering price
of up to $31,397,111 remained unsold under the sales agreement and a prior sales agreement prospectus and related prospectus supplement dated May&nbsp;6, 2016, which we refer to in this prospectus as the prior prospectus. The common stock remaining
available to be sold under the prior prospectus as of the date of this prospectus will no longer be offered and sold under the prior prospectus, but will instead be offered and sold under this prospectus. Accordingly, this prospectus covers the
offer and sale of $70,000,000 to be sold under the amended sales agreement as of the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed
on The NASDAQ Global Market under the symbol &#147;CERS.&#148; The last reported sale price of our common stock on The NASDAQ Global Market on January&nbsp;4, 2018 was $3.72 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any, under this prospectus may be made in sales deemed to be &#147;at the market offerings&#148; as defined in
Rule&nbsp;415 promulgated under the Securities Act of 1933, as amended. Cantor will act as sales agent on a best efforts basis and use commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by
us, consistent with its normal trading and sales practices, on mutually agreed terms between Cantor and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cantor will be entitled to compensation under the terms of the amended sales agreement at a fixed commission rate of up to 3.0% of the gross
sales price per share sold. In connection with the sale of the common stock on our behalf, Cantor will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act, and the compensation of Cantor will be deemed to be
underwriting commissions or discounts. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. Please read the information contained in and incorporated by reference under
the heading &#147;<A HREF="#toc2486222_3">Risk Factors</A>&#148; on page 3 of this prospectus, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516993g38z19.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
January 8, 2018. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">i</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_4">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_8">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2486222_13">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">12</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge you to
carefully read this prospectus, together with the information incorporated by reference as described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this
prospectus. These documents contain important information that you should consider when making your investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
describes the specific terms of the common stock we are offering and also adds to, and updates information contained in the documents incorporated by reference into this prospectus. To the extent there is a conflict between the information contained
in this prospectus, on the one hand, and the information contained in any document incorporated by reference into this prospectus that was filed with the Securities and Exchange Commission, or SEC, before the date of this prospectus, on the other
hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference into this
prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on
the information contained in, or incorporated by reference into, this prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and Cantor has not, authorized any other person to
provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and Cantor is not, making an offer to sell or soliciting an offer to buy our common stock in any
jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the
information appearing in this prospectus, the documents incorporated by reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those
respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference into this prospectus, and any free writing
prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of
this prospectus entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by
reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and this
offering, we encourage you to read and consider carefully the more detailed information in this prospectus, including the information incorporated by reference into this prospectus, and the information included in any free writing prospectus that we
may authorize for use in connection with this offering, including the information referred to under the heading &#147;Risk Factors&#148; in this prospectus on page&nbsp;3 and in the documents incorporated by reference into this prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biomedical products
company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to reduce blood-borne
pathogens in donated blood components intended for transfusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our INTERCEPT Blood System is for use with three blood components:
plasma, platelets, and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received a broad range of regulatory approvals, including but not limited to U.S.
Food and Drug Administration, or FDA, approval in the U.S., and Class&nbsp;III CE marks in the European Union and other jurisdictions that recognize CE mark approval, and are being marketed and sold in a number of countries around the world,
including the U.S.; certain countries in Europe, the Commonwealth of Independent States, the Middle East, and Latin America and selected countries in other regions of the world. We sell both the platelet and plasma systems using our direct sales
force and through distributors. The INTERCEPT Blood System for red blood cells, or the red blood cell system, is currently in clinical development. If we are unable to gain widespread commercial adoption in markets where our blood safety products
are approved for commercialization, including in the U.S., we will have difficulties achieving profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to successfully
commercialize all of our products and product candidates, we will be required to conduct significant research, development, preclinical and clinical evaluation, commercialization and regulatory compliance activities for our products and product
candidates, which, together with anticipated increased selling, general and administrative expenses, are expected to result in substantial losses. Accordingly, we may never achieve a profitable level of operations in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated
in California in 1991 and reincorporated in Delaware in 1996. Our corporate address is 2550 Stanwell Drive, Concord, California 94520, and our telephone number is (925) <FONT STYLE="white-space:nowrap">288-6000.</FONT> Our website address is<I>
www.cerus.com</I>. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this prospectus, and you should not consider it part of this prospectus. Our website address is included in this document as
an inactive textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, as used in this prospectus, the terms &#147;Cerus,&#148;
&#147;Cerus Corporation,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Cerus Corporation, a Delaware corporation, and its wholly-owned subsidiary, Cerus Europe B.V. Cerus, INTERCEPT and INTERCEPT Blood System are U.S. registered
trademarks of Cerus Corporation. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us pursuant to this prospectus</P></TD>
<TD>Shares of common stock having an aggregate offering price of up to $70,000,000. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Manner of offering </P></TD>
<TD>&#147;At the market offering&#148; that may be made from time to time through our agent, Cantor. See &#147;Plan of Distribution&#148; on page 10 of this prospectus. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We intend to use the net proceeds from this offering, if any, for working capital and general corporate purposes, including research and development expenses, selling, general and administrative expenses and manufacturing expenses. See &#147;Use
of Proceeds&#148; on page 5 of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">NASDAQ Global Market listing </P></TD>
<TD>CERS </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>Investing in our common stock involves a high degree of risk. Please read the information contained in and incorporated by reference under the heading &#147;Risk Factors&#148; on page 3 of this prospectus and under similar headings in the other
documents that are filed after the date hereof and incorporated by reference into this prospectus, together with the other information included in or incorporated by reference into this prospectus, before deciding whether to invest in our common
stock. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should consider
carefully the risks and uncertainties described below and discussed under the section entitled &#147;Risk Factors&#148; contained in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended
September&nbsp;30, 2017, which are incorporated by reference into this prospectus in their entirety, as updated or superseded by the risks and uncertainties described under similar headings in the other documents that are filed after the date hereof
and incorporated by reference into this prospectus, together with the other information in this prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering. The
risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse
effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our
business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also carefully read the
section below entitled &#147;Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Risks Related to This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management will have broad discretion as to the use of the proceeds from this offering, and may not use the proceeds effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have not designated the amount of net proceeds from this offering to be used for any particular purpose, our management will have
broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of the offering. Our management may use the net proceeds for corporate purposes that may not
improve our financial condition or market value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this
offering. Assuming that an aggregate of 18,817,204&nbsp;shares of our common stock are sold at a price of $3.72 per share pursuant to this prospectus, which was the last reported sale price of our common stock on The NASDAQ Global Market on
January&nbsp;4, 2018, for aggregate gross proceeds of $70.0&nbsp;million, after deducting commissions and estimated aggregate offering expenses payable by us, you would experience immediate dilution of $2.93 per share, representing the difference
between our as adjusted net tangible book value per share as of September&nbsp;30, 2017, after giving effect to this offering and the assumed offering price. The exercise of outstanding stock options may result in further dilution of your
investment. See the section entitled &#147;Dilution&#148; below for a more detailed illustration of the dilution you would incur if you participate in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or
exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors
in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or
exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay dividends in the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never paid cash dividends on our common stock and currently do not plan to pay any cash dividends in the foreseeable future.
Additionally, we would be required to obtain the written consent of the lenders under our amended and restated loan and security agreement with Oxford Finance LLC prior to declaring or paying any cash dividends. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_4"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, the documents we have filed with the SEC that are incorporated by reference and any free writing prospectus that we have
authorized for use in connection with this offering contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual
results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These forward-looking statements may include, but are not limited to,
statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future sales of and our ability to effectively commercialize and achieve market acceptance of the INTERCEPT Blood System, including our ability to comply with applicable U.S. and foreign laws, regulations and regulatory
requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manage the growth of our business and attendant cost increases, including in connection with the commercialization of the INTERCEPT Blood System in the United States, as well as our ability to manage the
risks attendant to our international operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing or likelihood of regulatory submissions and approvals and other regulatory actions or interactions, including our anticipated CE mark submission for the red blood cell system; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain regulatory approvals of the INTERCEPT Blood System; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain adequate clinical and commercial supplies of the INTERCEPT Blood System from our sole source suppliers for a particular product or component they manufacture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, scope, rate of progress, results and timing of our ongoing and proposed preclinical studies and clinical trials of the INTERCEPT Blood System; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the successful completion of our research, development and clinical programs and our ability to manage cost increases associated with preclinical and clinical development of the INTERCEPT Blood System;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount and availability of funding we may receive under our agreement with the Biomedical Advanced Research and Development Authority; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to transition distribution of the INTERCEPT Blood System from third parties to a direct sales model in certain international markets; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of our products to inactivate the emerging viruses and other pathogens that we may target in the future; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the anticipated use of proceeds from this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding the sufficiency of our cash resources and our need for additional funding. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;anticipate,&#148; &#147;will,&#148; &#147;believe,&#148;
&#147;estimate,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;may,&#148; &#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;project,&#148; &#147;predict,&#148; &#147;potential,&#148; and similar
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expressions intended to identify such forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and
uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail, and incorporate by reference into this prospectus in their entirety, many of these risks and
uncertainties under the heading &#147;Risk Factors&#148; contained on page 3 of this prospectus and in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2017, which is incorporated
herein by reference, as may be updated or superseded by the risks and uncertainties described under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus. Also, these
forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, the documents we have filed with the SEC that are incorporated by reference and any free writing prospectus
we have authorized for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing
documents by these cautionary statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless required by law, we undertake no obligation to update or revise any forward-looking
statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any free writing prospectus that we may authorize to be provided to you, we currently intend to use the net proceeds
from this offering, if any, for working capital and general corporate purposes, including research and development expenses, selling, general and administrative expenses and manufacturing expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our use of the net proceeds from this offering will depend on a number of factors, such as the timing and progress
of our research and development efforts, the timing and progress of any partnering and commercialization efforts, technological advances and the competitive environment for our products. As of the date of this prospectus, we cannot specify with
certainty all of the particular uses for the net proceeds to us from this offering. Accordingly, our management will have broad discretion in the timing and application of these proceeds. Pending application of the net proceeds as described above,
we intend to temporarily invest the proceeds in short-term, interest-bearing instruments. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_6"></A>DIVIDEND POLICY
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid dividends on our common stock and do not intend to pay cash dividends on our common stock in the
foreseeable future. Additionally, we would be required to obtain the written consent of the lenders under our amended and restated loan and security agreement with Oxford Finance LLC prior to declaring or paying any cash dividends. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in this offering, your ownership interest will be diluted to the extent of the difference between the public offering price per
share and the as adjusted net tangible book value per share after giving effect to this offering. We calculate net tangible book value per share by dividing the net tangible book value, which is tangible assets less total liabilities, by the number
of outstanding shares of our common stock. Dilution represents the difference between the portion of the amount per share paid by purchasers of shares in this offering and the as adjusted net tangible book value per share of our common stock
immediately after giving effect to this offering. Our net tangible book value as of September&nbsp;30, 2017, was approximately $35.3&nbsp;million, or $0.31 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of our common stock pursuant to this prospectus in the aggregate
amount of $70.0&nbsp;million at an assumed offering price of $3.72 per share, the last reported sale price of our common stock on The NASDAQ Global Market on January&nbsp;4, 2018, and after deducting commissions and estimated aggregate offering
expenses payable by us, our net tangible book value as of September&nbsp;30, 2017 would have been $103.7&nbsp;million, or $0.79 per share of common stock. This represents an immediate increase in the net tangible book value of $0.48 per share to our
existing stockholders and an immediate dilution in net tangible book value of $2.93 per share to new investors. The following table illustrates this per share dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of September&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share as of September&nbsp;30, 2017, after giving effect
to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above assumes for illustrative purposes that an aggregate of 18,817,204&nbsp;shares of our common
stock are sold pursuant to this prospectus at a price of $3.72 per share, the last reported sale price of our common stock on The NASDAQ Global Market on January&nbsp;4, 2018, for aggregate gross proceeds of $70.0&nbsp;million. The shares are being
sold from time to time at various prices pursuant to the amended sales agreement with Cantor. An increase of $0.50 per share in the price at which the shares are sold from the assumed offering price of $3.72 per share shown in the table above,
assuming all of our common stock in the aggregate amount of $70.0&nbsp;million is sold at that price, would increase our adjusted net tangible book value per share after the offering to $0.80 per share and would increase the dilution in net tangible
book value per share to new investors in this offering to $3.42 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $0.50 per share in the price at which the shares are sold from the assumed
offering price of $3.72 per share shown in the table above, assuming all of our common stock in the aggregate amount of $70.0&nbsp;million is sold at that price, would decrease our adjusted net tangible book value per share after the offering to
$0.77 per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $2.45 per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is
supplied for illustrative purposes only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 112,214,393 shares of our common stock issued and
outstanding as of September&nbsp;30, 2017, and excludes, as of that date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">17,379,309 shares of common stock issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $4.29 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,286,381 shares of common stock issuable upon the vesting of restricted stock units; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">up to an aggregate of 8,848,455 shares of common stock remaining available for future issuance under our 2008 Equity Incentive Plan and 1996 Employee Stock Purchase Plan. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that options outstanding as of September&nbsp;30, 2017, have been or are exercised, or other shares are issued, investors
purchasing shares in this offering could experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future
operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_8"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our amended and restated certificate of incorporation (as amended), or the Restated Certificate, authorizes
us to issue 225,000,000 shares of common stock, par value $0.001 per share, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
5,000,000 shares of preferred stock, par value $0.001 per share. As of January&nbsp;4, 2018, 115,554,634&nbsp;shares of common stock were outstanding. As of the date of this prospectus, our board
of directors has also designated 5,000 of the 5,000,000 authorized shares of preferred stock as Series&nbsp;A Preferred Stock, and 250,000 of the 5,000,000 authorized shares of preferred stock as Series&nbsp;C Junior Participating Preferred Stock.
As of the date of this prospectus, no shares of our Series&nbsp;A Preferred Stock or Series&nbsp;C Junior Participating Preferred Stock are outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary description of our capital stock is based on the provisions of the Restated Certificate, our amended and restated
bylaws, the applicable provisions of the Delaware General Corporation Law and the agreements described below. This information may not be complete in all respects and is qualified entirely by reference to the provisions of the Restated Certificate,
our amended and restated bylaws, the Delaware General Corporation Law and such agreements. For information on how to obtain copies of the Restated Certificate, our amended and restated bylaws and such agreements, which are exhibits to the
registration statement of which this prospectus forms a part, see &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders.
Subject to preferences that may be applicable to any outstanding shares of our preferred stock, the holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of funds legally available
therefor. In the event of a liquidation, dissolution or winding up of our company, holders of the common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding
shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock. When we issue
shares of common stock under this prospectus, the shares will be fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional shares of authorized common
stock may be issued, as authorized by our board of directors from time to time, without stockholder approval, except as may be required by applicable stock exchange requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Restated
Certificate, our board of directors has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the designations, powers, preferences, privileges and relative
participating, optional or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater
than the rights of the common stock. The board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could adversely affect the voting power and other rights of the holders of common
stock. Preferred stock could thus be issued quickly with terms calculated to delay or prevent a change in control of our company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of
decreasing the market price of the common stock and may adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series A Preferred Stock. </I>All 5,000 shares of our Series A Preferred Stock were previously issued and outstanding and were subsequently
converted to shares of common stock in July 2002. Pursuant to the terms of the Series A Preferred Stock, these shares may not be reissued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series C Junior Participating Preferred Stock. </I>The Series C Junior Participating Preferred Stock, or Series C Preferred, is reserved
for issuance in connection with the rights outstanding under our Rights Agreement as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
described below. The Series C Preferred will not be redeemable. Each share of Series C Preferred will be entitled to a minimum preferential quarterly dividend payment of $1.00 per share but will
be entitled to an aggregate dividend of 100 times the dividend declared per share of common stock. In the event of liquidation, the holders of the Series C Preferred will be entitled to a minimum preferential liquidation payment of $100 per share
but will be entitled to an aggregate payment of 100 times the payment made per share of common stock. Each Series C Preferred share will have 100 votes, voting together with the shares of common stock. Finally, in the event of any merger,
consolidation or other transaction in which share of common stock are exchanged, each Series C Preferred share will be entitled to receive 100 times the amount of consideration received per share of common stock. These rights are protected by
customary anti-dilution provisions. Because of the nature of the Series C Preferred dividend, liquidation and voting rights, the value of the one <FONT STYLE="white-space:nowrap">one-hundredth</FONT> interest in a Series C Preferred share
purchasable upon exercise of each Right should approximate the value of one share of common stock. The Series C Preferred would rank junior to any other series of our preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Antitakeover Effects of Provisions of Charter Documents and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Charter Documents. </I>The Restated Certificate and our amended and restated bylaws, include a number of provisions that may have the effect
of deterring hostile takeovers or delaying or preventing changes in control or management of our company. First, our board of directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified
board may be removed only for cause unless the corporation&#146;s certificate of incorporation provides otherwise. The Restated Certificate does not provide otherwise. In addition, the Restated Certificate provides that all stockholder action must
be effected at a duly called meeting of stockholders and not by a consent in writing. Further, our amended and restated bylaws limit who may call special meetings of our stockholders. The Restated Certificate does not include a provision for
cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. Finally, our amended and restated bylaws establish
procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals. These and other provisions of the Restated Certificate and our amended and restated bylaws and Delaware
law could discourage potential acquisition proposals and could delay or prevent a change in control or management of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware Takeover Statute.</I> We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware, or DGCL, which
regulates acquisitions of some Delaware corporations. In general, Section&nbsp;203 prohibits, with some exceptions, a publicly held Delaware corporation such as us from engaging in a &#147;business combination&#148; with an &#147;interested
stockholder&#148; for a period of three years following the time that the stockholder became an interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the time the stockholder became an interested stockholder, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an
interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the number of shares outstanding (a)&nbsp;shares owned by persons who are directors and also officers and (b)&nbsp;employee stock plans in which employee participants do not have the right
to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at or subsequent to the time the stockholder became an interested stockholder, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written
consent, by the affirmative vote of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the outstanding voting stock which is not owned by the interested stockholder. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL generally defines a &#147;business combination&#148; to include any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) involving the interested stockholder of 10% or more of the assets of the corporation (or its
majority-owned subsidiary); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially
owned by the interested stockholder; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits,
other than certain benefits set forth in Section&nbsp;203, provided by or through the corporation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general,
Section&nbsp;203 defines an &#147;interested stockholder&#148; as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person that is an affiliate or associate of such entity or
person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL could depress our stock price and delay, discourage or prohibit transactions not approved in advance
by our board of directors, such as takeover attempts that might otherwise involve the payment to our stockholders of a premium over the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rights Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a
stockholder rights agreement, dated as of November&nbsp;3, 1999, and amended as of October&nbsp;28, 2009, or the Rights Agreement, pursuant to which each share of our common stock outstanding has attached to it a right, or Right. The Rights trade
with our common stock until the earlier to occur of (i)&nbsp;ten days after a public announcement that a person (or a group of affiliated or associated persons) has acquired beneficial ownership of 15% or more of the outstanding common stock, which
we refer to as an Acquiring Person, or (ii)&nbsp;ten business days (or such later date as may be determined by action of the board of directors prior to such time as any person or entity becomes an Acquiring Person) following the commencement of, or
announcement of an intention to make, a tender offer or exchange offer the consummation of which would result in the beneficial ownership by an Acquiring Person of 15% or more of the outstanding common stock. The earlier of these dates is called the
Distribution Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Distribution Date, the Rights will be evidenced by separate certificates. The Rights are not exercisable
until after the Distribution Date. Each Right entitles the holder to purchase, for $30 per Right, one <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a share of Series C Preferred, subject to adjustment. Each one <FONT
STYLE="white-space:nowrap">one-hundredth</FONT> of a share of Series C Preferred has designations and powers, preferences and rights, and the qualifications, limitations and restrictions designed to make it the economic equivalent of a share of
common stock. The expiration date of the Rights is October&nbsp;27, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any person (or a group of affiliated or
associated persons) becomes an Acquiring Person, proper provision shall be made so that each holder of a Right, other than Rights beneficially owned by the Acquiring Person or any affiliate or associate thereof (which will thereafter be void), will
thereafter have the right to receive upon exercise that number of shares of common stock having a market value of two times the exercise price of the Right. This right will commence on the date 10 days following public announcement that a person has
become an Acquiring Person (or the effective date of a registration statement relating to distribution of the rights, if later) and terminate 60 days later (subject to adjustment in the event exercise of the rights is enjoined). At the time the
rights flip in, they no longer represent the right to purchase shares of Series C Preferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Cerus is acquired in a
merger or other business combination transaction or 50% or more of its consolidated assets or earning power are sold to an Acquiring Person, its affiliates or associates or certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other persons in which such persons have an interest, proper provision will be made so that each holder of a Right will thereafter have the right to receive, upon the exercise thereof at the then
current exercise price of the Right, that number of shares of common stock of the acquiring company which at the time of such transaction will have a market value of two times the exercise price of the Right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the earliest of (i)&nbsp;the close of business on the day of the first public announcement that a person has become an
Acquiring Person, or (ii)&nbsp;October&nbsp;27, 2019, the board of directors may redeem the Rights in whole, but not in part, at a price of $0.001 per Right, or the Redemption Price. In general, the redemption of the Rights may be made effective at
such time, on such basis and with such conditions as the board of directors in its sole discretion may establish. Immediately upon any redemption of the Rights, the right to exercise the Rights will terminate and the only right of the holders of
Rights will be to receive the Redemption Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after the acquisition by a person (or a group of affiliated or associated
persons) of beneficial ownership of 15% or more of the outstanding shares of common stock and prior to the acquisition by such person or group of 50% or more of the outstanding shares of common stock, the board of directors may exchange the Rights
(other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock, or, under circumstances set forth in the Rights Agreement, cash, property or other securities of Cerus,
including fractions of a Series C Preferred (or of a share of a class or series of Cerus&#146; preferred stock having equivalent designations and the powers, preferences and rights, and the qualifications, limitations and restrictions), per Right
(with value equal to such shares of common stock). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the Rights may be amended by the board of directors without the consent
of the holders of the Rights, except that from and after such time as the Rights are distributed no such amendment may adversely affect the interests of the holders of the Rights (excluding the interest of any Acquiring Person). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Rights have certain anti-takeover effects. The Rights will cause substantial dilution to a person or group that attempts to acquire us on
terms not approved by our board of directors. The Rights should not interfere with any merger or other business combination approved by our board of directors since the Rights may be amended to permit such acquisition or redeemed by us at $0.001 per
Right prior to the earliest of (a)&nbsp;the time that a person or group has acquired beneficial ownership of 15% or more of the common stock or (b)&nbsp;the final expiration date of the rights, October&nbsp;27, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock is Wells Fargo Shareowner Services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on The NASDAQ Global Market </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Global Market under the symbol &#147;CERS.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into amendment No.&nbsp;3 to our existing Controlled Equity Offering<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP>
sales agreement with Cantor, pursuant to which we may issue and sell shares of our common stock through Cantor, acting as agent. In accordance with the terms of the amended sales agreement, we may offer and sell shares of our common stock under this
prospectus having an aggregate offering price of up to $70,000,000 from time to time through Cantor, acting as agent. As of immediately prior to the effectiveness of amendment No.&nbsp;3, shares of our common stock having an aggregate offering price
of up to $31,397,111 remained unsold under the sales agreement and a prior sales agreement prospectus and related prospectus supplement dated May&nbsp;6, 2016, which we refer to in this prospectus as the prior prospectus. The common stock remaining
available to be sold under the prior prospectus as of the date of this prospectus will no longer be offered and sold under the prior prospectus, but will instead be offered and sold under this prospectus. Accordingly, this prospectus covers the
offer and sale of $70,000,000 to be sold under the amended sales agreement as of the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary of the material provisions of the sales agreement does not purport to be a complete
statement of its terms and conditions. Copies of the sales agreement amendments and the sales agreement are filed with the SEC and are incorporated by reference into the registration statement of which this prospectus is a part. See &#147;Where You
Can Find More Information&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon delivery of a placement notice and subject to the terms and conditions of the sales
agreement, Cantor may sell our common stock by any method permitted by law deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act. Cantor may also sell the common stock in negotiated
transactions, subject to our prior approval. We or Cantor may suspend the offering of our common stock upon notice and subject to other conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay Cantor in cash, upon each sale of our common stock pursuant to the sales agreement, a commission in an amount equal to up to 3.0%
of the aggregate gross proceeds from each sale of our common stock. Cantor may effect sales to or through dealers, and such dealers may receive compensation in the form of discounts, concessions or commissions from Cantor and/or purchasers of shares
of common stock for whom they may act as agents or to whom they may sell as principal. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to
us, if any, are not determinable at this time. We estimate that the total expenses for the offering, excluding compensation and reimbursements payable to Cantor under the terms of the sales agreement, will be approximately $125,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Settlement for sales of common stock will occur on the third business day following the date on which any sales are made, or on some other
date that is agreed upon by us and Cantor in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as contemplated in this prospectus will be settled through the facilities of The
Depository Trust Company or by such other means as we and Cantor may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cantor will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase shares of
our common stock under the terms and subject to the conditions set forth in the sales agreement. In connection with the sale of the common stock on our behalf, Cantor will be deemed to be an &#147;underwriter&#148; within the meaning of the
Securities Act, and the compensation of Cantor will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to Cantor against certain civil liabilities, including liabilities under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering of common stock pursuant to the amended sales agreement will terminate upon the earlier of (i)&nbsp;the sale
of our common stock provided for in this prospectus, (ii)&nbsp;the date that is three years following the effective date of the registration statement of which this prospectus is a part, or (iii)&nbsp;termination of the amended sales agreement as
permitted therein. We and Cantor may each terminate the sales agreement at any time upon ten days&#146; prior notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cantor and its
affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M,
Cantor will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the accompanying prospectus in electronic format may be made available on a website maintained by Cantor, and Cantor may
distribute this prospectus and the accompanying prospectus electronically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP, San Francisco, California, has passed upon the validity of the common stock offered by this prospectus. Duane Morris LLP, Newark,
New Jersey, is counsel for Cantor in connection with this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2016, as set forth in their reports, which
are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports, given on their authority as experts in
accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the
Securities Act and do not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not
be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference in this prospectus for a copy of such contract, agreement or other document.
Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the
Internet at the SEC&#146;s website at http://www.sec.gov. You may also read and copy any document we file at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the operation of the Public Reference Room. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2486222_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we
filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus the information
or documents listed below that we have filed with the SEC (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;000-21937):</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, which was filed on March&nbsp;8, 2017, as amended by Amendment No.&nbsp;1 to Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> filed with the Commission on May&nbsp;31, 2017 (as amended, the &#147;2016 Form <FONT STYLE="white-space:nowrap">10-K&#148;);</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the information specifically incorporated by reference into the 2016 Form <FONT STYLE="white-space:nowrap">10-K</FONT> from our definitive proxy statement relating to our 2017 annual meeting of stockholders, which was
filed on April&nbsp;28, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2017, which was filed on May&nbsp;4, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2017, which was filed on August&nbsp;4, 2017; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2017, which was filed on November&nbsp;3, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> which were filed on April&nbsp;17, 2017, May&nbsp;24, 2017, June&nbsp;8, 2017, August&nbsp;2, 2017 and January&nbsp;5, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock in our registration statement on Form <FONT STYLE="white-space:nowrap">8-A</FONT> filed with the SEC on January&nbsp;8, 1997, including all amendments and reports filed for the
purpose of updating such description; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our preferred share purchase rights in our registration statement on Form <FONT STYLE="white-space:nowrap">8-A</FONT> filed with the SEC on October&nbsp;30, 2009, including all amendments and reports
filed for the purpose of updating such description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current
reports furnished under Item 2.02 or Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the
contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of
such registration statement, until we file a post-effective amendment that indicates the termination of the offering of the common stock made by this prospectus and will become a part of this prospectus from the date that such documents are filed
with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we
previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cerus Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2550 Stanwell
Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Concord, California 94520 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(925) <FONT STYLE="white-space:nowrap">288-6000</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:4.00pt solid #1269bc">&nbsp;</P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$70,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516993g41z17.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g516993g38z19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">January&nbsp;8, 2018 </P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:4.00pt solid #1269bc">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g516993g38z19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516993g38z19.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1O:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   LPF' )0  YM:6QL
M86YG87-I;F=H81P"!0 @36EC<F]S;V9T(%=O<F0@+2!#86YT;W)?;&]G;RYD
M;V, .$))300E       0X'D5P+FOAJ)0^)R5%8CWICA"24T$.@      Y0
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M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M \     !  (#P     $  CA"24T$)@      #@             _@   .$))
M300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          CA"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #-0    8              &,   $L
M      $                          0             !+    &,
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   &,
M4F=H=&QO;F<   $L    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   !C     %)G:'1L;VYG   !+
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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M*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_V0 X0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
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M&P %     0   4(!*  #     0 "   " 0 $     0   4H" @ $     0
M            2     $   !(     3A"24T#_0      "           _^$!
M3$U- "H    (  @!$@ #     0     !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M#P   +"':0 $     0   ,    #L   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#@Z,#4@,#DZ,C$Z,C< ;6EL
M;&%N9V%S:6YG:&$    #H $  P    '__P  H ( !     $   $LH , !
M  $   !C          8! P #     0 &   !&@ %     0   3H!&P %
M 0   4(!*  #     0 "   " 0 $     0   4H" @ $     0
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M 0$  @,! 0$              08"! 4' PC_Q  W$0 " 0,# @0#" $#!0$
M   ! @, !!$%$B$&$R(Q0? 446$',G&!D:'!T;$5(^$6)#-"\6+_V@ , P$
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M(-DDL[+[HZ8QGUI:-U%TGJ,UOIFF-%//V&9(S8RH%C@1=V9)K>-3@8QSSS]
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M&2$5?/:HP.T$*A)<<]1+36MKZ$4\+%$"IVEY!;42M^'2>8UC(4"81J:<1?\
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M>L^8I)-')-]04Z-#<'A;VMWKQS(F8JI+E$L"9F&E!Z3\0)+HKA]]W&V&26_
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M-*T4D\[N3@QB.3"(B1A!O*AB[  DDR \P_3,<CB:.@C3JA*9RF^MA[AS81.
M6(^%0](F[?NW#48#;[!\*+-A(U1D.5?*:IY(.FZ[S5%)-;1/6N7_ -I^KM>S
MMIL=M'8[@+=+FWWS; /O.4F W,2<C) P, >O1M>C[(01_&/*]S@]PP3%8L[C
MM"ADSPN,GC)R<"HJ+=^FB[6!7Q/I%S@3J9I50JR#)ZF,RBR2;>7#XHU.JDH8
MV,J:1A7&IH:ST8M7#K+C_6<M\N?DUSOG[;98_:5HCV,*:E\5\6;6,70BL_\
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8F>E*/2E'I2CTI1Z4H]*4>E*/2E'I2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g516993g41z17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516993g41z17.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[0G44&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  8     $  0!@     0 !.$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      !M    !@              &P   &@    & &< -  Q
M 'H ,0 W     0                         !              !H
M&P                                             X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     !S@    !    :    !L
M  $X   @Z   !QP &  !_]C_X  02D9)1@ ! @$ 2 !(  #_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  ; &@# 2(  A$! Q$!_]T !  '_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MN']36.M^LW6J[K;;J^GW.9BLLL>]K!ZEU>C7N/YE>U=P==%Q/U)_\5/UF_\
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M?9?^<SO2]+U-GO\ VA]H_:7'YGVK]7]/_P +_P"#224__]DX0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  -@ N #     ! #A"
M24T$!@      !P (  $  0$ _^X #D%D;V)E &1      ?_; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\  $0@ &P!H P$1
M  (1 0,1 ?_=  0 #?_$ *\   ,!  (#              @)"@8%!P "! $
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*+9T.*1]G^*+_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
